<DOC>
	<DOC>NCT02083653</DOC>
	<brief_summary>This is a Phase 2, open-label, 3-arm trial of two Sym004 doses (Arms A and B) and a control group (Arm C) in subjects with metastatic colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs).</brief_summary>
	<brief_title>Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Written informed consent obtained before undergoing any studyrelated activities Male or female, at least 18 years of age Subjects with histologically or cytologically confirmed mCRC, Kirsten rat sarcoma wildtype (KRAS WT) at initial diagnosis Failure of or intolerance to 5FU, Oxaliplatin, and Irinotecan Acquired resistance to marketed antiEGFR mAbs as defined in the protocol Measurable disease defined as one or more target lesions according to RECIST Life expectancy of at least 3 months Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1 Other protocol defined inclusion criteria could apply Pretreatment with regorafenib. Subjects who in the opinion of the subject and investigator would benefit more from regorafenib treatment (except where regorafenib is not reimbursed in the country) Skin rash Common Terminology Criteria for AEs (CTCAE) Grade greater than 1 from previous antiEGFR therapy at time of randomization Magnesium less than 0.9 milligram per deciliter (mg/dL) Known hypersensitivity to any of the treatment ingredients. Known previous Grade 34 infusion related reactions with antiEGFR mABs Other protocol defined exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>Sym004</keyword>
	<keyword>Best Supportive Care</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Fluorouracil (5-FU)</keyword>
</DOC>